Risk stratification for hepatitis B virus related hepatocellular carcinoma

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 1, 2013, Pages 10-17

  Lin, Chih Lin ^a,b   Kao, Jia Horng ^c,d  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL CHENGCHI UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

HBV genotype; HBV mutants; HBV DNA; Hepatitis B virus (HBV); Hepatocellular carcinoma; Quantitative HBsAg; Risk stratification

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIGEN; VIRUS DNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER RISK; DELETION MUTANT; FEMALE; GENOTYPE; HEPATITIS B; HUMAN; LIVER CELL CARCINOMA; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; VIRUS CARRIER; VIRUS LOAD; VIRUS MUTANT; VIRUS REPLICATION;

EID: 84871660571     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12010     Document Type: Article

References (73)

1. Kao JH, Chen DS. Global control of hepatitis B virus infection. Lancet Infect. Dis. 2002; 2: 395-403.
2. Kao JH, Chen PJ, Chen DS. Recent advances in the research of hepatitis B virus-related hepatocellular carcinoma: epidemiologic and molecular biological aspects. Adv. Cancer Res. 2010; 108: 21-72.
3. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003; 46: 400-407.
4. Lin CL, Kao JH, Hepatitis B. Viral factors and clinical outcomes of chronic hepatitis B. J. Biomed. Sci. 2008; 15: 137-145.
5. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting liver cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686.
6. Chen CJ, Yang HI, Su J etal. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73.
7. McMahon BJ. The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B. Hepatol. Int. 2009; 3: 334-342.
8. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol. Res. 2010; 40: 14-30.
9. Cao GW. Clinical relevance and public health significance of hepatitis B virus genomic variations. World J. Gastroenterol. 2009; 15: 5761-5769.
10. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers. J. Med. Virol. 2004; 72: 363-369.
11. Kao JH, Chen PJ, Lai MY, Chen DS. Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J. Clin. Microbiol. 2002; 40: 1207-1209.
12. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002; 122: 1756-1762.
13. Kao JH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000; 118: 554-559.
14. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-334.
15. Yuen MF, Tanaka Y, Mizokami M etal. Role of hepatitis B virus genotypes B and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis 2004; 25: 1593-1598.
16. Chan HL, Hui AY, Wong ML etal. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004; 53: 1494-1498.
17. Yang HI, Yeh SH, Chen PJ etal. REVEAL-HBV Study Group. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J. Natl. Cancer Inst. 2008; 100: 1134-1143.
18. Ni YH, Chang MH, Wang KJ etal. Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma. Gastroenterology 2004; 127: 1733-1738.
19. Yin J, Zhang H, Li C etal. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area. Carcinogenesis 2008; 29: 1685-1691.
20. Lin CL, Liao LY, Wang CS etal. Basal core-promoter mutant of hepatitis B virus and progression of liver disease in hepatitis B e antigen-negative chronic hepatitis B. Liver Int. 2005; 25: 564-570.
21. Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J. Gastroenterol. 2006; 12: 6620-6626.
22. Liu CJ, Chen BF, Chen PJ etal. Role of hepatitis B viral load and basal core promoter mutation in hepatocellular carcinoma in hepatitis B carriers. J. Infect. Dis. 2006; 193: 1258-1265.
23. Liu CJ, Chen BF, Chen PJ etal. Role of hepatitis B virus precore/core promoter mutations and serum viral load on noncirrhotic hepatocellular carcinoma: a case-control study. J. Infect. Dis. 2006; 194: 594-599.
24. Liu S, Zhang H, Gu C etal. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J. Natl. Cancer Inst. 2009; 101: 1066-1082.
25. Gerken G, Kremsdorf D, Capel F etal. Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection. Virology 1991; 183: 555-565.
26. Fernholz D, Stemler M, Brunetto M, Bonino F, Will H. Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein. J. Hepatol. 1991; 13: S102-104.
27. Fan YF, Lu CC, Chen WC etal. Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 2001; 33: 277-286.
28. Tai PC, Suk FM, Gerlich WH, Neurath AR, Shih C. Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants. Virology 2002; 292: 44-58.
29. Su IJ, Wang HC, Wu HC, Huang WY. Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection. J. Gastroenterol. Hepatol. 2008; 23: 1169-1174.
30. Hsieh YH, Su IJ, Wang HC etal. Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage. Carcinogenesis 2004; 25: 2023-2032.
31. Lin CL, Wu PY, Chang WL etal. Clinical significance of hepatitis B virus pre-S deletion mutants in patients with chronic hepatitis B virus infection: a case-control study. Gastroenterol. J. Taiwan 2009; 26: 171-179.
32. Lin CL, Liu CH, Chen W etal. Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 2007; 22: 1098-1103.
33. Chen CH, Hung CH, Lee CM etal. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients. Gastroenterology 2007; 133: 1466-1474.
34. Fang ZL, Sabin CA, Dong BQ etal. Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study. J. Gen. Virol. 2008; 89: 2882-2890.
35. Bruss V. A short linear sequence in the pre-S domain of the large hepatits B virus envelope protein required for virion formation. J. Virol. 1997; 71: 9350-9357.
36. Sobotta D, Sominskaya I, Jansons J etal. Mapping of immune dominant B-cell epitopes and the human serum albumin-binding site in natural hepatitis B virus surface antigen of defined genosubtype. J. Gen. Virol. 2000; 81: 369-378.
37. Chen BF, Liu CJ, Jow GM, Chen PJ, Kao JH, Chen DS. High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases. Gastroenterology 2006; 130: 1153-1168.
38. Kao JH, Liu CJ, Jow GM, Chen PJ, Chen DS, Chen BF. Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma. Liver Int. 2012; 32: 1373-1381.
39. Robinson WS. The genome of hepatitis B virus. Annu. Rev. Microbiol. 1977; 31: 357-377.
40. Beck J, Nassal M. Hepatitis B virus replication. World J. Gastroenterol. 2007; 13: 48-64.
41. Heermann KH, Goldmann U, Schwartz W, Seyffarth T, Baumgarten H, Gerlich WH. Large surface proteins of hepatitis B virus containing the pre-s sequence. J. Virol. 1984; 52: 396-402.
42. Heermann KH, Kruse F, Seifer M, Gerlich WH. Immunogenicity of the gene S and Pre-S domains in hepatitis B virions and HBsAg filaments. Intervirology 1987; 28: 14-25.
43. Ou JH, Laub O, Rutter WJ. Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc. Natl. Acad. Sci. U.S.A. 1986; 83: 1578-1582.
44. Liaw YF. Clinical utility of hepatitis B surface antigen quantitation in patients with chronic hepatitis B: a review. Hepatology 2011; 53: 2121-2129.
45. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology 2002; 122: 1554-1568.
46. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662.
47. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J. Hepatol. 2012; 57: 167-185.
48. Liaw YF, Leung N, Kao JH etal. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol. Int. 2012; 6: 531-561.
49. Chen CJ, Yang HI. Natural history of chronic hepatitis B REVEALed. J. Gastroenterol. Hepatol. 2011; 26: 628-638.
50. Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol. 2006; 101: 1797-1803.
51. Tseng TC, Liu CJ, Chen CL etal. Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J. Infect. Dis. 2012; 205: 54-63.
52. Tsai FC, Liu CJ, Chen CL etal. Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. J. Viral Hepat. 2007; 14: 153-160.
53. Chan HL, Thompson A, Martinot-Peignoux M etal. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J. Hepatol. 2011; 55: 1121-1131.
54. Nguyen T, Desmond P, Locarnini S. The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B. Hepatol. Int. 2009; 3: S5-15.
55. Brunetto MR. A new role for an old marker, HBsAg. J. Hepatol. 2010; 52: 475-477.
56. Chan HL, Wong VW, Tse AM etal. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin. Gastroenterol. Hepatol. 2007; 5: 1462-1468.
57. Thompson AJV, Nguyen T, Iser D etal. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010; 51: 1933-1944.
58. Jaroszewicz J, Serrano BC, Wursthorn K etal. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J. Hepatol. 2010; 52: 514-522.
59. Su TH, Hsu CS, Chen CL etal. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir. Ther. 2010; 15: 1133-1139.
60. Brunetto MR, Oliveri F, Colombatto P etal. Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers. Gastroenterology 2010; 139: 483-490.
61. Tseng TC, Liu CJ, Su TH etal. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology 2011; 141: 517-525.
62. Tseng TC, Liu CJ, Yang HC etal. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load. Hepatology 2012; 55: 68-76.
63. Chen C, Lee M, Liu J etal. Quantitative serum levels of hepatitis B virus DNA and surface antigen are independent risk of hepatocellular carcinoma (Abstract). Hepatology 2011; 54: 881A.
64. Tseng TC, Liu CJ, Yang HC etal. High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.
65. Chen JD, Yang HI, Iloeje UH etal. Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer in HBV (REVEAL-HBV) Study Group. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology 2010; 138: 1747-1754.
66. Tseng TC, Liu CJ, Yang HC etal. Serum hepatitis B surface antigen levels help predict disease progression in patients with low HBV loads. Hepatology 2012. doi: 10.1002/hep.26041.
67. Han KH, Ahn SH. How to predict HCC development in patients with chronic B viral liver disease? Intervirology 2005; 48: 23-28.
68. Yuen MF, Tanaka Y, Fong DY etal. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J. Hepatol. 2009; 50: 80-88.
69. Wong VW, Chan SL, Mo F etal. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J. Clin. Oncol. 2010; 28: 1660-1665.
70. Yang HI, Sherman M, Su J etal. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J. Clin. Oncol. 2010; 28: 2437-2444.
71. Yang HI, Yuen MF, Chan HL etal. REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. Lancet Oncol. 2011; 12: 568-574.
72. Yu MW, Yeh SH, Chen PJ etal. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J. Natl. Cancer Inst. 2005; 97: 265-272.
73. Chen CH, Changchien CS, Lee CM etal. Combined mutations in pre-s/surface and core promoter/precore regions of hepatitis B virus increase the risk of hepatocellular carcinoma: a case-control study. J. Infect. Dis. 2008; 198: 1634-1642.